スパイロメーター - 市場考察、競合情勢、市場予測（2030年）

世界のスパイロメーターの市場規模は、2030年までに18億166万米ドルに達すると予測され、2024年～2030年の予測期間にCAGRで4.65%の成長が見込まれます。市場は、複数の主な要因によって大きな成長を示す見込みです。第一に、慢性閉塞性肺疾患（COPD）や喘息を含む呼吸器疾患の負担の増加は、効果的な診断とモニタリングツールの必要性を強調し、それによってスパイロメーターの需要を増加させます。タバコ喫煙の急増は呼吸器疾患をさらに悪化させ、疾患の管理と進行予防のための定期的な肺機能検査の必要性を高めています。さらに、呼吸器の健康に対する意識の高まりと広範な検診プログラムの実施は、早期の発見と介入を促進し、標準的な診断ツールとしてのスパイロメトリーの採用を促進しています。さらに、主要市場企業が継続的に技術革新を行い、改良された機能と技術を備えた先進のスパイロメトリーデバイスを発表しているため、製品の発売と承認が増加し、市場は強化されています。これらの要因は、2024年～2030年の予測期間にスパイロメーター市場の拡大に総体的に寄与すると予測されます。

スパイロメーターの市場力学

Australian Institute of Health and Welfareが提供した最新データによると、2022年にオーストラリアで約850万人（34%）が慢性呼吸器疾患を患っていると推定されています。

また、Global Burden of Disease（2023年）の最新データによると、世界では約20人に1人が慢性呼吸器疾患を患っています。

さらに、世界保健機関（WHO）が提供した近年のデータ（2023年）によると、喫煙は慢性閉塞性肺疾患の主因であり、これは呼吸困難につながる一般的な肺疾患で、年間300万人以上の命を奪っています。約3億9,200万人がCOPDを患っており、その約75％が低中所得国に住んでいます。高所得国では、タバコ喫煙がCOPD症例の70％以上を占めています。

喫煙や環境要因によって呼吸器疾患の罹患率が上昇するにつれ、効果的な症状緩和と疾患管理に向けて肺に直接薬剤を投与するのに不可欠なスパイロメーターへのニーズが高まっています。

さらに、GLOBOCANが提供した近年のデータによると、2022年に世界で新たに発生したと推定される気管、気管支、肺のがんの患者は248万人であり、2045年までに425万人増加すると予測されています。COPDは主に喫煙によって引き起こされる進行性の呼吸器疾患であり、症状を管理し、疾患の進行を追跡するために、定期的な肺機能の評価が必要です。COPDの有病率が上昇するにつれて、医療提供者は肺活量と気流閉塞を評価するスパイロメーターへの依存度を高めており、これらの機器は診断と継続的な管理の両方に不可欠となっています。同様に、喫煙率の急増はCOPDを含む呼吸器疾患の罹患率の上昇につながり、スパイロメトリー検査の必要性を高めています。喫煙者や元喫煙者は、損傷の兆候を早期に発見し、それ以上の悪化を防ぐために、定期的な肺機能スクリーニングの対象となることが多いです。

さらに、企業はスパイロメーターの生産を拡大し、規制当局の承認を確保することで、市場でのプレゼンスを戦略的に拡大し、さらなる成長を促進しています。例えば2024年1月、NuvoAir Medicalは、同社の革新的なAir Next Spirometerが、完全なスパイロメーターとして家庭内で使用するための正式な510（k）認可を取得したと発表しました。この認可により、NuvoAirは臨床事業の規模を拡大し、心臓や肺の疾患を持つ患者を1人も取り残さないようにすることができました。

さらに、スパイロメトリーに関する臨床試験の成功は、市場に大きな弾みをつけ、成長見通しを高め、関心と投資の増加を促しました。例えば2023年1月、エビデンスに基づくデジタルバイオマーカーを開発した医療技術企業Koneksaは、臨床試験の開始を発表しました。この研究では、長時間作用性β作動薬（LABA）治療を受けている中等度喘息患者を対象に、デジタルバイオマーカーを用いた自宅でのモバイルスパイロメトリーと診療所でのスパイロメトリーの治療効果を比較しました。

このように、上記の要因が予測期間にスパイロメーター市場を押し上げる可能性が高いです。

しかし、ピークフローメーター、カプノメーター、イメージング技術、パルスオキシメーターなどの代替のデバイスが利用可能であることが、将来のスパイロメーター市場の妨げになる可能性があります。

当レポートでは、世界のスパイロメーター市場について調査分析し、各地域の市場規模と予測、過去3年間の製品/技術開発、各セグメントの業績と見通しなどの情報を提供しています。

目次

第1章 スパイロメーター市場レポートのイントロダクション

第2章 スパイロメーター市場のエグゼクティブサマリー

• 市場の概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 スパイロメーター市場の主な要因の分析

• スパイロメーター市場の促進要因
• スパイロメーター市場の抑制要因と課題
• スパイロメーター市場の機会

第6章 スパイロメーター市場のポーターのファイブフォース分析

第7章 スパイロメーター市場の評価

• タイプ別
  • 卓上
  • 携帯可能
• 可動性別
  • 体積測定
  • 流量測定
• 用途別
  • 喘息
  • 慢性閉塞性肺疾患（COPD）
  • 嚢胞性線維症
  • その他
• エンドユーザー別
  • 病院
  • 診療所
  • 在宅ケア
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 スパイロメーター市場の企業と製品のプロファイル

• FUKUDA SANGYO CO., LTD.
• Midmark Corporation
• CHEST M.I., Inc.
• KoKo PFT
• Clarity Medical Pvt. Ltd.
• COSMED srl
• Jones Medical Instrument Company
• Baxter
• Teleflex Incorporated
• VYAIRE MEDICAL, INC.
• SIBEL, S.A.U.
• Medikro Oy
• ICU Medical Inc.
• Vitalograph
• Futuremed USA
• Schiller AG
• Aksia Group SGR S.p.A
• CONTEC MEDICAL SYSTEMS CO., LTD.
• NDD Medical Technologies
• MGC DIAGNOSTICS CORPORATION

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Spirometers Market in Global (2021-2030)
• Table 3: Spirometers Market in Global by Type (2021-2030)
• Table 4: Spirometers Market in Global by Technology (2021-2030)
• Table 5: Spirometers Market in Global by Application (2021-2030)
• Table 6: Spirometers Market in Global by End-User (2021-2030)
• Table 7: Spirometers Market in Global by Geography (2021-2030)
• Table 8: Spirometers Market in North America (2021-2030)
• Table 9: Spirometers Market in the United States (2021-2030)
• Table 10: Spirometers Market in Canada (2021-2030)
• Table 11: Spirometers Market in Mexico (2021-2030)
• Table 12: Spirometers Market in Europe (2021-2030)
• Table 13: Spirometers Market in France (2021-2030)
• Table 14: Spirometers Market in Germany (2021-2030)
• Table 15: Spirometers Market in United Kingdom (2021-2030)
• Table 16: Spirometers Market in Italy (2021-2030)
• Table 17: Spirometers Market in Spain (2021-2030)
• Table 18: Spirometers Market in the Rest of Europe (2021-2030)
• Table 19: Spirometers Market in Asia-Pacific (2021-2030)
• Table 20: Spirometers Market in China (2021-2030)
• Table 21: Spirometers Market in Japan (2021-2030)
• Table 22: Spirometers Market in India (2021-2030)
• Table 23: Spirometers Market in Australia (2021-2030)
• Table 24: Spirometers Market in South Korea (2021-2030)
• Table 25: Spirometers Market in Rest of Asia-Pacific (2021-2030)
• Table 26: Spirometers Market in the Rest of the World (2021-2030)
• Table 27: Spirometers Market in the Middle East (2021-2030)
• Table 28: Spirometers Market in Africa (2021-2030)
• Table 29: Spirometers Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Spirometers Market in Global (2021-2030)
• Figure 3: Spirometers Market in Global by Type (2021-2030)
• Figure 4: Spirometers Market in Global by Technology (2021-2030)
• Figure 5: Spirometers Market in Global by Application (2021-2030)
• Figure 6: Spirometers Market in Global by End-User (2021-2030)
• Figure 7: Spirometers Market in Global by Geography (2021-2030)
• Figure 8: Spirometers Market in North America (2021-2030)
• Figure 9: Spirometers Market in the United States (2021-2030)
• Figure 10: Spirometers Market in Canada (2021-2030)
• Figure 11: Spirometers Market in Mexico (2021-2030)
• Figure 12: Spirometers Market in Europe (2021-2030)
• Figure 13: Spirometers Market in France (2021-2030)
• Figure 14: Spirometers Market in Germany (2021-2030)
• Figure 15: Spirometers Market in United Kingdom (2021-2030)
• Figure 16: Spirometers Market in Italy (2021-2030)
• Figure 17: Spirometers Market in Spain (2021-2030)
• Figure 18: Spirometers Market in the Rest of Europe (2021-2030)
• Figure 19: Spirometers Market in Asia-Pacific (2021-2030)
• Figure 20: Spirometers Market in China (2021-2030)
• Figure 21: Spirometers Market in Japan (2021-2030)
• Figure 22: Spirometers Market in India (2021-2030)
• Figure 23: Spirometers Market in Australia (2021-2030)
• Figure 24: Spirometers Market in South Korea (2021-2030)
• Figure 25: Spirometers Market in Rest of Asia-Pacific (2021-2030)
• Figure 26: Spirometers Market in the Rest of the World (2021-2030)
• Figure 27: Spirometers Market in the Middle East (2021-2030)
• Figure 28: Spirometers Market in Africa (2021-2030)
• Figure 29: Spirometers Market in South America (2021-2030)
• Figure 30: Market Drivers
• Figure 31: Market Barriers
• Figure 32: Market Opportunities
• Figure 33: PORTER'S Five Force Analysis

Spirometers by Type (Table Top and Portable), Technology (Volume Measurement and Flow Measurement), Application (Asthma, Chronic Obstructive Pulmonary Disease [COPD], Cystic Fibrosis, and Others), End-User (Hospitals, Clinics, and Home Care), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising burden of respiratory diseases, the surge in cigarette smoking, increasing awareness and screening programs, and increase in product launches and approvals by key market players across the globe.

The spirometer market will grow at a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 1,801.66 million by 2030. The market for spirometer is set to experience significant growth driven by several key factors. Firstly, the rising burden of respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, underscores the need for effective diagnostic and monitoring tools, thereby increasing the demand for spirometer. The surge in cigarette smoking further exacerbates respiratory conditions, heightening the necessity for routine lung function testing to manage and prevent disease progression. Additionally, increasing awareness about respiratory health and the implementation of widespread screening programs are fostering early detection and intervention, which fuels the adoption of spirometry as a standard diagnostic tool. Furthermore, the market is being bolstered by a rise in product launches and approvals from key market players, who are continuously innovating and introducing advanced spirometry devices with improved features and technology. These factors are expected to collectively contribute to the expanding market for spirometer during the forecast period from 2024 to 2030.

Spirometers Market Dynamics:

According to the latest data provided by the Australian Institute of Health and Welfare, in 2022, around 8.5 million (34%) people in Australia were estimated to have chronic respiratory conditions.

Additionally, as per the recent data provided by the Global Burden of Disease (2023), approximately, 1 in 20 people globally suffers from chronic respiratory diseases.

Furthermore, as per the recent data provided by the World Health Organization (2023), smoking was a major cause of chronic obstructive pulmonary disease, a common lung condition that led to breathing difficulties and claimed over 3 million lives annually. Approximately 392 million people have COPD, with about 75% living in low- and middle-income countries. In high-income countries, tobacco smoking was responsible for over 70% of COPD cases.

As the incidence of respiratory disorders rises, driven largely by smoking and environmental factors, there is a heightened need for Spirometers, which are critical in delivering medication directly to the lungs for effective symptom relief and disease management.

Additionally, as per the recent data provided by GLOBOCAN, in 2022, globally the estimated new cases of trachea, bronchus, and lung cancer was 2.48 million, and the projections are expected to rise by 4.25 million by the year 2045. COPD, a progressive respiratory condition primarily caused by smoking, requires regular assessment of lung function to manage symptoms and track disease progression. As COPD prevalence rises, healthcare providers are increasingly relying on spirometer to evaluate lung capacity and airflow obstruction, making these devices essential for both diagnosis and ongoing management. Similarly, the surge in smoking rates contributes to a higher incidence of respiratory disorders, including COPD, which in turn drives the need for spirometry tests. Smokers and former smokers are often targeted for regular lung function screening to detect early signs of damage and prevent further deterioration.

Additionally, companies are amplifying their production of spirometer and securing regulatory approvals, thereby strategically expanding their market presence and driving further growth. For instance, in January 2024, NuvoAir Medical announced that its innovative Air Next Spirometer had received formal 510(k) clearance for in-home use as a full spirometer. This approval allowed NuvoAir to scale and expand its clinical operations, ensuring that no patient with heart or lung conditions was left behind.

Moreover, the success of the clinical trial on spirometry gave a significant boost to the market, enhancing its growth prospects and driving increased interest and investment. For instance, in January 2023, Koneksa, a healthcare technology company that developed evidence-based digital biomarkers, announced the launch of a clinical study. The study compared the treatment effects of at-home mobile spirometry using digital biomarkers with in-clinic spirometry in patients with moderate asthma who were on long-acting beta-agonist (LABA) treatment.

Thus, the factors mentioned above are likely to boost the market of spirometers during the forecasted period.

However, the availability of alternative devices such as peak flow meters, capnometers, imagining techniques, and pulse oximeters may hinder the future market of spirometers.

Spirometers Market Segment Analysis:

Spirometers by Type (Table Top and Portable), Technology (Volume Measurement and Flow Measurement), Application (Asthma, Chronic Obstructive Pulmonary Disease [COPD], Cystic Fibrosis, and Others), End-User (Hospitals, Clinics, and Home Care), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the spirometer market, the portable spirometer is expected to hold a significant share in 2023. Portable spirometers are significantly boosting the overall spirometer market by enhancing accessibility and convenience for both patients and healthcare providers. These compact, handheld devices allow for real-time monitoring of lung function outside of traditional clinical settings, enabling patients to conduct tests at home or on the go. This increased accessibility is particularly valuable for managing chronic respiratory conditions like asthma and COPD, where regular monitoring is crucial. Portable spirometers also facilitate early detection and intervention, as patients can perform frequent tests without needing to visit a healthcare facility. Additionally, advancements in connectivity and integration with mobile health apps have enabled seamless data sharing with healthcare providers, improving remote patient management and personalized care. The growing adoption of portable spirometers reflects a shift towards more proactive and patient-centered healthcare, driving market growth as these devices become an integral part of routine respiratory health management.

In addition, new product launches are also likely to upsurge the global spirometer market during the forecasted period. For instance, in November 2021, Cipla announced the launch of Spirofy(R), India's first pneumotach-based portable, wireless spirometer, on World COPD Day. With this launch, the company aimed to revolutionize the diagnosis of Obstructive Airway Disease (OAD) and strengthen its position as a leader in lung health in India. This was part of the Company's LungAttack campaign, which sought to raise awareness about COPD and promote early diagnosis. Additionally, a shift in trend from table-top to portable devices will offer assistance in remote settings. This will increase the acceptance of spirometers for patients.

Hence, all the above-mentioned factors are expected to generate considerable revenue for the segment pushing the overall growth of the global spirometer market during the forecast period.

North America is expected to dominate the overall spirometer market:

North America is expected to account for the highest proportion of the spirometer market in 2023, out of all regions. This can be ascribed to the increasing prevalence of respiratory disease across the region, the increase in technological advancement, the surge in cigarette smoking, the increase in government initiatives coupled with increased awareness programs for respiratory disorders, and the presence of key market players engaged in merger, acquisition, product launches, and other market activities across the region are expected to escalate the market of Spirometers during the forecast period.

According to the recent data and stats provided by the American Lung Association (2024), in 2022, among children, asthma was more common in males accounting for 7.0% of the population in the United States and 5.4% in females. Additionally, as per the same source, asthma among adults is 10.8% for females and 6.5% for females across the region of the United States. Asthma management requires regular monitoring of lung function to adjust treatment plans and prevent exacerbations. Spirometers allow patients to track their lung function over time, providing critical data to healthcare providers for optimizing treatment strategies. This continuous need for monitoring drives the market for both in-clinic and portable spirometers.

Additionally, as per the data provided by the Centre for Disease Control and Prevention (2024), in 2022, 4.6% of adults had been diagnosed with COPD, emphysema, or chronic bronchitis in the United States.

Furthermore, as per the recent data and stats provided by the Centre for Disease Control and Prevention (2023), in 2021, approximately 11.5% of U.S. adults aged 18 and older smoked cigarettes, totaling around 28.3 million smokers. At that time, over 16 million Americans were living with a smoking-related disease. The spirometer market is significantly boosted by the increasing prevalence of chronic respiratory conditions such as COPD, emphysema, and chronic bronchitis, alongside rising smoking rates. These conditions, which are often exacerbated by smoking, require regular and accurate monitoring of lung function for effective management and treatment. Spirometers are essential tools for diagnosing and tracking these diseases, as they measure vital lung parameters such as airflow and lung volume.

The increasing number of product development activities in the region is further going to accelerate the growth of the spirometer market. For instance, in August 2021, Roundworks Technologies Private Limited announced the approval of 510(k) for its Alveoair Digital Spirometer. Alveoair(R) is a personal spirometer designed for asthma, COPD, cystic fibrosis, and ILD patients to help quantify their lung health.

Furthermore, in March 2023, Clario, a healthcare research technology company known for its endpoint technology solutions for clinical trials, announced a partnership with the technology startup ArtiQ. This collaboration aimed to improve the accuracy of respiratory clinical trials that require spirometry data. The partnership allowed for AI-based reviews of spirometry data collected on the Clario platform.

Therefore, the above-mentioned factors are expected to bolster the growth of the spirometer market in North America during the forecast period.

Spirometers Market Key Players:

Some of the key market players operating in the Spirometers market include FUKUDA SANGYO CO., LTD., Midmark Corporation, CHEST M.I., Inc., KoKo PFT, Clarity Medical Pvt. Ltd., COSMED srl, Jones Medical Instrument Company, Baxter, Teleflex Incorporated, VYAIRE MEDICAL, INC., SIBEL, S.A.U., Medikro Oy, ICU Medical Inc., Vitalograph, Futuremed USA, Schiller AG, Aksia Group SGR S.p.A, CONTEC MEDICAL SYSTEMS CO., LTD, NDD Medical Technologies, MGC DIAGNOSTICS CORPORATION, and others.

Recent Developmental Activities in the Spirometers Market:

• In September 2022, RxCap, Inc., a cloud-based remote monitoring company, and ZEPHYRx LLC, a provider of remote respiratory monitoring solutions, announced their partnership to integrate ZEPHYRx's cloud spirometry platform with RxCap's remote monitoring platform.
• In March 2022, KoKo, LLC, a software developer and medical device manufacturer, and MAGNET group, a purchasing organizations (GPO) company signed a three-year partnership contract that allows access to all of KoKo's "gold standard" lung function diagnostics and software for spirometry, diffusion capacity, and PFT.

Key Takeaways From the Spirometers Market Report Study:

• Market size analysis for current spirometer size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the spirometer market.
• Various opportunities available for the other competitors in the spirometer market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current spirometer market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for spirometer market growth in the coming future?

Target Audience who can be Benefited From This Spirometers Market Report Study:

• Spirometers product providers
• Research organizations and consulting companies
• Spirometers -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in spirometer
• Various end-users who want to know more about the spirometer market and the latest technological developments in the spirometer market.

Frequently Asked Questions for the Spirometers Market:

1. What are spirometers?

The spirometer is a medical device that is used for performing spirometry tests to examine the function of the lungs. It is a very valuable tool for studying multiple respiratory problems such as asthma, chronic obstructive pulmonary disease (COPD), and others. It is also used to evaluate possible occupational pulmonary disorders and can be used to test lung functioning before surgery.

2. What is the market for spirometers?

The spirometer market will grow at a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 1,801.66 million by 2030.

3. What are the drivers for the spirometer market?

The spirometer market is set to experience significant growth driven by several key factors. Firstly, the rising burden of respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, underscores the need for effective diagnostic and monitoring tools, thereby increasing the demand for spirometers. The surge in cigarette smoking further exacerbates respiratory conditions, heightening the necessity for routine lung function testing to manage and prevent disease progression. Additionally, increasing awareness about respiratory health and the implementation of widespread screening programs are fostering early detection and intervention, which fuels the adoption of spirometry as a standard diagnostic tool. Furthermore, the market is being bolstered by a rise in product launches and approvals from key market players, who are continuously innovating and introducing advanced spirometry devices with improved features and technology. These factors are expected to collectively contribute to the expanding market for spirometers during the forecast period from 2024 to 2030.

4. Who are the key players operating in the spirometer market?

Some of the key market players operating in the Spirometers market include FUKUDA SANGYO CO., LTD., Midmark Corporation, CHEST M.I., Inc., KoKo PFT, Clarity Medical Pvt. Ltd., COSMED srl, Jones Medical Instrument Company, Baxter, Teleflex Incorporated, VYAIRE MEDICAL, INC., SIBEL, S.A.U., Medikro Oy, ICU Medical Inc., Vitalograph, Futuremed USA, Schiller AG, Aksia Group SGR S.p.A, CONTEC MEDICAL SYSTEMS CO., LTD, NDD Medical Technologies, MGC DIAGNOSTICS CORPORATION, and others.

5. Which region has the highest share in the spirometer market?

North America is expected to account for the highest proportion of the spirometer market in 2023, out of all regions. This can be ascribed to the increasing prevalence of respiratory disease across the region, the increase in technological advancement, the surge in cigarette smoking, the increase in government initiatives coupled with increased awareness programs for respiratory disorders, and the presence of key market players engaged in merger, acquisition, product launches, and other market activities across the region are expected to escalate the market of Spirometers during the forecast period.

Table of Contents

1. Spirometers Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Spirometers Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Spirometers Market Key Factors Analysis

• 5.1. Spirometers Market Drivers
  • 5.1.1. The rising burden of chronic respiratory diseases
  • 5.1.2. The surge in cigarette smoking
  • 5.1.3. Increasing awareness and screening programs
  • 5.1.4. Increase in product launches and approvals by key market players across the globe.
• 5.2. Spirometers Market Restraints and Challenges
  • 5.2.1. The availability of alternative devices such as peak flow meters, capnometers, imagining techniques, and pulse oximeters
• 5.3. Spirometers Market Opportunities
  • 5.3.1. The increase in the shift towards home-based healthcare solutions
  • 5.3.2. Integration of digital health and artificial intelligence

6. Spirometers Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Spirometers Market Assessment

• 7.1. By Type
  • 7.1.1. Table Top
  • 7.1.2. Portable
• 7.2. By Portability
  • 7.2.1. Volume Measurement
  • 7.2.2. Flow Measurement
• 7.3. By Application
  • 7.3.1. Asthma
  • 7.3.2. Chronic Obstructive Pulmonary Disease (COPD)
  • 7.3.3. Cystic Fibrosis
  • 7.3.4. Others
• 7.4. By End-User
  • 7.4.1. Hospitals
  • 7.4.2. Clinics
  • 7.4.3. Homecare
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Spirometers Market Size in USD Million (2021-2030)
    • 7.5.1.2. Canada Spirometers Market Size in USD Million (2021-2030)
    • 7.5.1.3. Mexico Spirometers Market Size in USD Million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Spirometers Market Size in USD Million (2021-2030)
    • 7.5.2.2. Germany Spirometers Market Size in USD Million (2021-2030)
    • 7.5.2.3. United Kingdom Spirometers Market Size in USD Million (2021-2030)
    • 7.5.2.4. Italy Spirometers Market Size in USD Million (2021-2030)
    • 7.5.2.5. Spain Spirometers Market Size in USD Million (2021-2030)
    • 7.5.2.6. Rest of Europe Spirometers Market Size in USD Million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Spirometers Market Size in USD Million (2021-2030)
    • 7.5.3.2. Japan Spirometers Market Size in USD Million (2021-2030)
    • 7.5.3.3. India Spirometers Market Size in USD Million (2021-2030)
    • 7.5.3.4. Australia Spirometers Market Size in USD Million (2021-2030)
    • 7.5.3.5. South Korea Spirometers Market Size in USD Million (2021-2030)
    • 7.5.3.6. Rest of Asia-Pacific Spirometers Market Size in USD Million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Spirometers Market Size in USD Million (2021-2030)
    • 7.5.4.2. Africa Spirometers Market Size in USD Million (2021-2030)
    • 7.5.4.3. South America Spirometers Market Size in USD Million (2021-2030)

8. Spirometers Market Company and Product Profiles

• 8.1. FUKUDA SANGYO CO., LTD.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Midmark Corporation
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. CHEST M.I., Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. KoKo PFT
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Clarity Medical Pvt. Ltd.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. COSMED srl
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Jones Medical Instrument Company
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Baxter
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Teleflex Incorporated
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. VYAIRE MEDICAL, INC.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. SIBEL, S.A.U.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Medikro Oy
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. ICU Medical Inc.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Vitalograph
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Futuremed USA
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Schiller AG
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Aksia Group SGR S.p.A
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. CONTEC MEDICAL SYSTEMS CO., LTD.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. NDD Medical Technologies
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. MGC DIAGNOSTICS CORPORATION
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us